Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 29, 2017

DrugPatentWatch Database Preview

MECLIZINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

Which patents cover Meclizine Hydrochloride, and what generic alternatives are available?

Meclizine Hydrochloride is a drug marketed by Superpharm, Vangard, Kv Pharm, Par Pharm, Pliva, Mylan Pharms Inc, Watson Labs, Sandoz, Amneal Pharms, Abc Holding, UDL, Ani Pharms Inc, Jubilant Cadista, Bundy, Ivax Sub Teva Pharms, Rising Pharms Inc, Anabolic, Nexgen Pharma Inc, and Epic Pharma Llc. and is included in thirty-four NDAs.

The generic ingredient in MECLIZINE HYDROCHLORIDE is meclizine hydrochloride. There are seventeen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the meclizine hydrochloride profile page.

Summary for Tradename: MECLIZINE HYDROCHLORIDE

Patents:0
Applicants:19
NDAs:34
Suppliers / Packagers: see list40
Bulk Api Vendors: see list101
Clinical Trials: see list991
Patent Applications: see list4,124
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MECLIZINE HYDROCHLORIDE at DailyMed

Pharmacology for Tradename: MECLIZINE HYDROCHLORIDE

Drug ClassAntiemetic
Physiological EffectEmesis Suppression
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
MECLIZINE HYDROCHLORIDE
meclizine hydrochloride
TABLET;ORAL085195-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Rising Pharms Inc
MECLIZINE HYDROCHLORIDE
meclizine hydrochloride
TABLET;ORAL040179-001Jan 30, 1997DISCNNoNo► Subscribe► Subscribe
Par Pharm
MECLIZINE HYDROCHLORIDE
meclizine hydrochloride
TABLET;ORAL089674-001Mar 31, 1988DISCNNoNo► Subscribe► Subscribe
Rising Pharms Inc
MECLIZINE HYDROCHLORIDE
meclizine hydrochloride
TABLET;ORAL040179-002Jan 30, 1997DISCNNoNo► Subscribe► Subscribe
Ani Pharms Inc
MECLIZINE HYDROCHLORIDE
meclizine hydrochloride
TABLET;ORAL084975-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Find generic sources and suppliers
  • Predict branded drug patent expiration
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot